BACKGROUND: The FlutterVRP1 combines high frequency oscillation and positive expiratory pressure (PEP). OBJECTIVE: To separately evaluate the effect of the FlutterVRP1 components (high frequency oscillation and PEP) on mucus transportability in patients with bronchiectasis. METHODS: Eighteen patients with bronchiectasis received sessions with the FlutterVRP1 or PEP for 30 min daily in a randomized, crossover study. The treatment duration was four weeks with one of the therapies, one week of a "wash-out" period and followed by four more weeks with the other treatment. Weekly secretion samples were collected and evaluated for mucociliary relative transport velocity (RTV), displacement in a simulated cough machine (SCM) and contact angle measurement (CAM). For the proposed comparisons, a linear regression model was used with mixed effects with a significance level of 5%. RESULTS: The FlutterVRP1 treatment resulted in greater displacement in SCM and lower CAM when comparing results from the first (9.6 +/- 3.4 cm and 29.4 +/- 5.7 degrees, respectively) and fourth weeks of treatment (12.44 +/- 10.5 cm and 23.28 +/- 6.2 degrees, respectively; p < 0.05). There was no significant difference in the RTV between the treatment weeks for either the FlutterVRP1 or PEP. CONCLUSION: The use of the FlutterVRP1 for four weeks is capable of altering the respiratory secretion transport properties, and this alteration is related to the high frequency oscillation component.

Full text (sometimes free) may be available at these link(s):      help

• DOI
• PubMed
• PDF locator
• publisher